The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz) for the moderate to severe population, together with additional emerging agents with novel MOAs and a general increase in the use of biologics, will help to drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio) expands physicians’ treatment armamentarium and intensifies market competition. In balance with these factors, the entry of generics for leading branded conventional agents (e.g., Shire’s Lialda), continuing generic erosion of other conventional agents, and additional entries/expanded uses of less expensive biosimilar TNF-alpha inhibitors (e.g., Pfizer’s Inflectra, Amgen’s Amjevita) will constrain the UC market. Indeed, emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.
- What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
- How do gastroenterologists perceive biosimilar agents, and what impact have/will these agents have on the UC market?
- What are KOLs’ insights into current treatment options (e.g., AbbVie/Eisai’s Humira, Pfizer’s Xeljanz)? What factors drive their treatment decisions?
- What are KOLs’ perceptions of key emerging therapies (e.g., AbbVie’s upadacitinib, Roche/Genentech’s etrolizumab, Janssen’s Stelara, Celgene’s ozanimod), and where do they see these agents fitting into the treatment algorithm?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.